Clinical trials: Locally Advanced Cervical Cancer
Disease Free Survival
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concurrent chemoradiotherapy (CCRT)…
- Trial name
- NCT04138992
- Testing
- bevacizumab, DDP, Docetaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Air Force Military Medical University, China
Salivary Gland Neoplasms
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or…
- Trial name
- YATAGARASU (NCT04325828)
- Testing
- Apalutamide, GnRH Agonist
- Where
- 7 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Janssen Pharmaceutical K.K.
Locally Advanced Cervical Cancer
Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy…
- Trial name
- NICE-CC (NCT07055399)
- Testing
- neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
This is a phase 2/window of opportunity study to determine the efficacy, by clinical complete response, and safety of induction toripalimab (PD-1 inhibitor) followed by definitive chemoradiotherapy (dCRT) and adjuvant toripalimab…
- Trial name
- NCT07836049
- Testing
- Toripalimab, Carboplatin + Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Head and Neck Carcinoma
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
- Trial name
- NeckTAR-IN (NCT07178847)
- Testing
- blood sampling
- Where
- 4 sites in France
- Volunteers
- 59 people
- Sponsor
- Centre Jean Perrin
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Esophageal Squamous Cell Carcinoma
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This is a prospective, single-arm, open-label，multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.
- Trial name
- NCT05896787
- Testing
- AK104, nab-paclitaxel, carboplatin
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses) and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib, cisplatin and radiation in the locally advanced…
- Trial name
- NCT00627835
- Testing
- sorafenib, sorafenib and cisplatin
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression
- Trial name
- NCT07446049
- Testing
- CVL237 tablets
- Volunteers
- 180 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Nasopharyngeal Carcinoma
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally…
- Trial name
- NCT06059261
- Testing
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Exploring the safety and effectiveness of neoadjuvant therapy using benmelstobart combined with anlotinib and chemotherapy for locally advanced squamous cell carcinoma of the head and neck patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
- Trial name
- NCT06699498
- Testing
- Benmelstobart, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cancer of Cervix
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
The propose of this study is to determine if neoadjuvant chemotherapy followed by chemoradiation is safe and effective in locally advanced cervical cancer patients.
- Trial name
- NCT02309658
- Testing
- gemcitabine, cisplatin, chemoradiation
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Professor Fernando Figueira Integral Medicine Institute
Cervical Cancer
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer.
- Trial name
- NCT02635360
- Testing
- Pembrolizumab, Brachytherapy, Cisplatin
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Linda R Duska
Cervical Cancer
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00023660
- Testing
- celecoxib, cisplatin, fluorouracil
- Where
- 36 sites in United States
- Volunteers
- 84 people
- Sponsor
- Radiation Therapy Oncology Group
HNSCC
Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.
- Trial name
- NCT04861467
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal…
- Trial name
- NCT03427359
- Testing
- cisplatin, capecitabine
- Volunteers
- 65 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Thyroid Cancer
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474…
- Trial name
- NCT00410761
- Testing
- ZD6474 (Vandetanib)
- Where
- 127 sites in United States, Australia and 22 more
- Volunteers
- 331 people
- Sponsor
- Genzyme, a Sanofi Company
Cervical Cancer
Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer
Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiation (CRT). Although recently reported meta-analysis studies also demonstrated improved local control rates and survival with…
- Trial name
- TACO (NCT01561586)
- Testing
- Weekly cisplatin with RT, Tri-weekly cisplatin with RT
- Where
- 15 sites in China, South Korea and 2 more
- Volunteers
- 374 people
- Sponsor
- Korea Cancer Center Hospital
Cervical Cancer
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.
Based on the Phase I trial completed by the sponsor, the Phase II clinical trial aims to investigate the effectiveness and safety of image guidance volume-modulated arc radiation therapy concurrently with Nab-Paclitaxel plus…
- Trial name
- NCT06426056
- Testing
- radiotherapy, Nab paclitaxel, Cisplatin
- Volunteers
- 64 people
- Sponsor
- Peking University Third Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.